← Back to Search

Growth Factor

Keratinocyte growth factor for Alopecia

Phase < 1
Waitlist Available
Led By Pavani Chalasani, MD
Research Sponsored by University of Arizona
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Diagnosed with early stage breast cancer (stage I-III)
≥ 21 years of age
Timeline
Screening 3 weeks
Treatment Varies
Follow Up four months
Awards & highlights

Study Summary

This trial is testing a new topical formula to see if it can prevent hair loss from chemotherapy.

Eligible Conditions
  • Alopecia
  • Chemotherapy-Induced Change

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~four months
This trial's timeline: 3 weeks for screening, Varies for treatment, and four months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Part 1: Preliminary assessment of the efficacy of the investigational topical formula, KGF-HS measuring hair loss after chemotherapy.
Alopecia
Secondary outcome measures
Estimate participant reported comfort.
Evaluate hair regrowth.
Evaluate quality of life using BIS.
+6 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Part 1 - Initial group treatmentExperimental Treatment1 Intervention
For part 1 of the study, subjects will be enrolled into a prospective single arm phase where all of them get the study treatment. We plan to enroll up to 25 subjects to have 20 evaluable subjects to this phase.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Keratinocyte growth factor
2020
Completed Early Phase 1
~30

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor
511 Previous Clinical Trials
148,260 Total Patients Enrolled
1 Trials studying Alopecia
50 Patients Enrolled for Alopecia
Pavani Chalasani, MDPrincipal InvestigatorUniversity of Arizona
7 Previous Clinical Trials
910 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the fundamental aims of this trial?

"This clinical trial will last for approximately four months, and its primary purpose is to gauge the effectiveness of KGF-HS as a topical formula against hair loss caused by chemotherapy. Other objectives include assessing hair preservation with the Alopecial Pictoral Tool (CTCAE v4.0 grades 0-2), evaluating regrowth speed in comparison to control groups, and gauging quality of life through HADS scores ranging from 0 to 21 (normal: 0-7; borderline case: 8-10; abnormal: 11-21)."

Answered by AI

Are any openings remaining for participants in this medical trial?

"Reputable sources at clinicaltrials.gov demonstrate that this medical investigation is presently not recruiting participants, having been initially posted on April 27th 2020 and last revised on June 15th 2022. Fortunately, there are 86 alternative trials actively enrolling patients currently."

Answered by AI
~6 spots leftby Mar 2025